By: Angela Garrity
The most valuable brands in America are not out of reach of the FDA when it comes to marketing of products, as Curaleaf is the next in line to receive a warning letter, Markets Insider reports.
Four of the company’s cannabidiol products designates them as drugs, as "intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease." The government agency specifically calls out Curaleaf’s CBD Lotion, CBD Pain-Relief Patch, CBD Tincture and CBD Disposable Vape Pen as “new drugs”, which the FDA requires approval of before they can be introduced into interstate commerce.
Since the CBD products are not "generally recognized as safe and effective" for the uses Curaleaf describes, the FDA said the items require agency approval before hitting the market. The products are also misbranded, as their labeling doesn't include "adequate" usage directions, according to the FDA letter.
The agency also noted that the company's "Bido CBD for Pets" products were never approved as new animal drugs. The FDA found the products are intended for the "mitigation, treatment or prevention" of animal disease, therefore requiring federal approval.
The letter states that "introducing or delivering these products for introduction into interstate commerce for such uses" violates the Food, Drug and Cosmetic Act.
Read the full article here.